SPHK1 and non-small cell lung carcinoma: Although there are limited studies regarding the application of these inhibitors in NSCLC, there is no denying that targeting the SPHK1/S1P/S1PRs signaling cascade presents a potential treatment prospect in related diseases including NSCLC.